1 Drusano GL, "Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint" 45 : 13-22, 2001
2 Mouton JW, "Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141" 48 : 1713-1718, 2004
3 Ashima Lal, "Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta- Analysis" 대한감염학회 48 (48): 81-90, 2016
4 Lodise TP Jr, "Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy" 44 : 357-363, 2007
5 Ariano RE, "Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia" 39 : 32-38, 2005
6 Craig WA, "Killing and regrowth of bacteria in vitro:a review" 74 : 63-70, 1990
7 Zelenitsky S, "Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations" 49 : 4009-4014, 2005
8 Nicolau DP, "Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia" 17 : 497-504, 2001
9 Craig WA, "Continuous infusion of beta-lactam antibiotics" 36 : 2577-2583, 1992
10 Drusano GL, "Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'" 2 : 289-300, 2004